

In the claims:

Please amend claims 4, 5 and 6 and add new claims 7-15 as follows:

1. (Original) A inhibitor of cancer bone metastasis, wherein an inhibition substance of the activation of osteoclast caused by the degradation of a signaling molecule, TRAF6, in the activation of osteoclast, a suppressive substance of the differentiation from osteoclast precursor cells to mature osteoclasts, and/or a bone resorption inhibitor and/or a Cox2 synthesis inhibitor are combined.

2. (Original) A inhibitor of cancer bone metastasis, wherein an IL-12 production inducer as an inhibition substance of the activation of osteoclast caused by the degradation of a signaling molecule, TRAF6, in the activation of osteoclast, a tyrosine kinase inhibitor as a suppressive substance of the differentiation from osteoclast precursor cells to mature osteoclasts, and/or a bisphosphonate as a bone resorption inhibitor and/or a Cox2 synthesis inhibitor for inhibiting the stimulation of RANKL/RANK receptor are combined.

3. (Original) A inhibitor of cancer bone metastasis, wherein an inhibition substance of the activation of osteoclast caused by the degradation of a signaling molecule, TRAF6, in the activation of osteoclast, a suppressive substance of the differentiation from osteoclast precursor cells to mature osteoclasts, and/or a bone resorption inhibitor and/or a substance enhancing the production of osteoprotegerin are combined.

4. (Currently Amended) The inhibitor of cancer bone metastasis according to ~~any one of claims 1 to 3~~ claim 1, wherein the tyrosine kinase inhibitor has a selectively targeting effect to at least one receptor from the followings:

HER2/neu, HER3, HER4, c-kit, PDGFR, bcr-ab1 and EGFR.

5. (Currently Amended) The inhibitor of cancer bone metastasis according to ~~any one of claims 1 to 4~~ claim 1, wherein IL-12 production inducer is a substance having a β 1,3/1,6 glucan structure.

6. (Currently Amended) A method for preventing and treating cancer bone metastases by the inhibitor of cancer bone metastasis according to ~~any one of claims 1 to 5~~ claim 1.

7. (New) The inhibitor of cancer bone metastasis according to claim 2, wherein the tyrosine kinase inhibitor has a selectively targeting effect to at least one receptor from the followings:

HER2/neu, HER3, HER4, c-kit, PDGFR, bcr-ab1 and EGFR.

8. (New) The inhibitor of cancer bone metastasis according to claim 3, wherein the tyrosine kinase inhibitor has a selectively targeting effect to at least one receptor from the followings:

HER2/neu, HER3, HER4, c-kit, PDGFR, bcr-ab1 and EGFR.

9. (New) The inhibitor of cancer bone metastasis according to claim 2, wherein IL-12 production inducer is a substance having a β 1,3/1,6 glucan structure.

10. (New) The inhibitor of cancer bone metastasis according to claim 3, wherein IL-12 production inducer is a substance having a β 1,3/1,6 glucan structure.

11. (New) The inhibitor of cancer bone metastasis according to claim 4, wherein IL-12 production inducer is a substance having a β 1,3/1,6 glucan structure.

12. (New) A method for preventing and treating cancer bone metastases by the inhibitor of cancer bone metastasis according to claim 2.

13. (New) A method for preventing and treating cancer bone metastases by the inhibitor of cancer bone metastasis according to claim 3.

14. (New) A method for preventing and treating cancer bone metastases by the inhibitor of cancer bone metastasis according to claim 4.

15. (New) A method for preventing and treating cancer bone metastases by the inhibitor of cancer bone metastasis according to claim 5.